All studies
Phase 2 / Phase 3RecruitingInterventionalNCT07196722

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease (ICONIC-CD)

A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • Crohn Disease
I want to take partRefer a patient19 sites in India · 395 worldwide

At a glance

Phase
Phase 2 / Phase 3
Study type
Interventional
Sponsor
Janssen Research & Development, LLC
Enrolment target
1,092
Started
3 October 2025
Main results due (estimated)
19 September 2028
Study ends (estimated)
6 October 2032
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
Double (participant, investigator)
Sites
395 · 19 in India
First posted
29 September 2025
Registry updated
3 November 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Diagnosis of CD established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of CD
* Moderately to severely active CD based on CDAI criteria, defined as baseline (Week I-0) CDAI score \>=220 but \<=450 and either mean daily SF count \>=4, or mean daily AP score \>=2
* Moderately to severely active CD based on SES-CD criteria assessed by baseline (Week I-0) endoscopic evidence of active ileal and/or colonic CD as assessed during central review of the screening video ileocolonoscopy defined as a SES-CD \>= 6 for participants with colonic or ileocolonic disease, and SES-CD \>= 4 for participants with isolated ileal disease, based on the presence of ulceration in any 1 of the 5 ileocolonic segments
* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (beta-hCG) at screening and a negative urine pregnancy test at Week I-0 prior to administration of study intervention and agree to further pregnancy tests
* Demonstrated an inadequate response to, or failure to tolerate conventional therapy but naïve to advanced therapies (advanced drug therapy \[ADT\]-naïve) or inadequate response to (that is, primary or secondary nonresponse) or failure to tolerate advanced therapy defined as biologics and/or advanced oral agents for the treatment of CD- (ADT-inadequate responder \[IR\]) as defined in the protocol

Exclusion criteria:

* Has complications of CD, such as symptomatic strictures or stenoses, short gut syndrome, or any other manifestation, that may require surgery while enrolled in the study and/or could impair the use of instruments (such as CDAI) to assess response to study intervention
* Presence of a stoma or ostomy
* Participants with presence of active fistulas may be included if there is no surgery needed
* Colonic resection within 24 weeks before baseline or any other major surgery performed within 12 weeks before baseline
* Presence on screening colonoscopy of adenomatous colon polyps outside of an area of known colitis not removed before randomization

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

What participants receive

  • Experimental

    Induction Study 1: Icotrokinra Dose 1

    Participants will receive Icotrokinra dose 1 in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12.

    Drug: Icotrokinra

  • Experimental

    Induction Study 1: Icotrokinra Dose 2

    Participants will receive Icotrokinra dose 2 in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12.

    Drug: Icotrokinra

  • Placebo comparator

    Induction Study 1: Placebo

    Participants will receive matching placebo in Induction Study 1 up to Week 12. Subsequent treatment will be determined by the participant's response status at Week 12.

    Drug: Placebo

  • Experimental

    Induction Study 2: Icotrokinra

    Participants will receive Icotrokinra at the dose regimen determined in Induction Study 1 up to Week 12. Subsequent study treatment will be determined by the participant's response status at Week 12.

    Drug: Icotrokinra

  • Placebo comparator

    Induction Study 2: Placebo

    Participants will receive matching placebo for up to Week 12. Subsequent study treatment will be determined by the participant's response status at Week 12.

    Drug: Placebo

  • Experimental

    Maintenance Study: Icotrokinra Dose 1

    Participants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 of the induction study will be randomized to receive icotrokinra maintenance dose 1. Participants receiving Icotrokinra Dose 1 and meeting criteria for loss of response during the Maintenance Study will be eligibile for a single blinded dose adjustment to Icotrokinra Dose 2. After completion of the Maintenance Study through Week 40, eligible participants can participate in long-term extension (LTE).

    Drug: Icotrokinra

  • Experimental

    Maintenance Study: Icotrokinra Dose 2

    Participants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 of the induction study will be randomized to receive icotrokinra maintenance dose 2. Participants who were non-responders at Week 12 of the induction studies will also receive icotrokinra maintenance dose 2 but will not be randomized. After completion of the Maintenance Study through Week 40, eligible participants can participate in LTE.

    Drug: Icotrokinra

  • Placebo comparator

    Maintenance Study: Placebo

    Participants who were receiving icotrokinra in either induction studies 1 or 2 and were in response at Week 12 will be randomized to receive placebo. Participants receiving placebo in induction studies 1 or 2 and in response at Week 12 of the induction study will continue to receive placebo during maintenance on non-randomized basis. Placebo non-responders from induction study will receive icotrokinra maintenance dose 2 on a non-randomized basis and will be assessed for response at Week 12. Participants receiving placebo and meeting criteria for loss of response during the Maintenance Study will be eligible for a single blinded dose adjustment to icotrokinra dose 2. After completion of the Maintenance Study through Week 40, eligible participants can participate in LTE.

    Drug: Icotrokinra · Drug: Placebo

Interventions

  • IcotrokinraDrug

    Also known as JNJ-77242113

    Icotrokinra will be administered orally, daily.

  • PlaceboDrug

    Matching placebo will be administered orally, daily.

What the study measures

Primary outcomes

  1. Induction Study 1: Number of Participants with Clinical Response at Week 12

    Clinical response is defined as a greater than or equal to (\>=) 100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) score. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 12

  2. Induction Study 2: Number of Participants with Clinical Remission at Week 12 (Co-Primary Endpoint)

    Clinical remission is defined as CDAI score less than (\<) 150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 12

  3. Induction Study 2: Number of Participants with Endoscopic Response at Week 12 (Co-Primary Endpoint)

    Endoscopic response is defined as greater than (\>) 50% improvement from baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.

    Time frame: At Week 12

  4. Maintenance Study: Number of Participants with Clinical Remission at Week 40 (Co-Primary Endpoint)

    Clinical remission is defined as CDAI score \< 150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 40

  5. Maintenance Study: Number of Participants with Endoscopic Response at Week 40 (Co-Primary Endpoint)

    Endoscopic response is defined as \> 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.

    Time frame: At Week 40

Secondary outcomes

  1. Induction Study 1: Number of Participants with Clinical Remission at Week 12

    Clinical remission is defined as CDAI score \< 150. CDAI scores ranging from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 12

  2. Induction Study 1: Number of Participants with Endoscopic Response at Week 12

    Endoscopic response is defined as \> 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.

    Time frame: At Week 12

  3. Induction Study 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.

    Time frame: Up to 4 weeks after last dose of study drug (i.e., up to Week 16)

  4. Induction Study 2: Number of Participants with Patient Reported Outcomes (PRO)-2 Remission at Week 12

    PRO-2 remission is defined as an abdominal pain (AP) mean daily score less than or equal to (\<=) 1 and stool frequency (SF) mean daily score \<= 2.8, and no worsening of AP or SF from baseline.

    Time frame: At Week 12

  5. Induction Study 2: Number of Participants with Clinical Response at Week 12

    Clinical response is defined as a \>= 100-point reduction from baseline in CDAI score.

    Time frame: At Week 12

  6. Induction Study 2: Number of Participants Reporting Both Clinical Remission and Endoscopic Response at Week 12

    Clinical remission is defined as CDAI score \< 150. Endoscopic response is defined as \> 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. This is a composite endpoint defined to measure achievement of both clinical remission and endoscopic response at the participant level.

    Time frame: At Week 12

  7. Induction Study 2: Number of Participants with Clinical Response at Week 4

    Clinical response is defined as a \>= 100-point reduction from baseline in CDAI score.

    Time frame: At Week 4

  8. Induction Study 2: Number of Participants with Endoscopic Remission at Week 12

    Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component.

    Time frame: At Week 12

  9. Induction Study 2: Number of Participants with Deep Remission at Week 12

    Deep remission is a composite endpoint defined as achieving both clinical remission and endoscopic remission at the participant level. Clinical remission is defined as CDAI score \< 150-point. Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component.

    Time frame: At Week 12

  10. Induction Study 2: Number of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 12

    IBDQ remission is defined as IBDQ score \>= 170. IBDQ is a validated, 32-item, self-reported questionnaire for participants with inflammatory bowel disease (IBD) that will be used to evaluate the disease-specific health-related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.

    Time frame: At Week 12

  11. Induction Study 2: Number of Participants with Fatigue Response at Week 12

    Fatigue response is defined as a \>= 7 point reduction in the patient reported outcomes measurement information system (PROMIS)-Fatigue Short Form 7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise). Item responses are rated on a five-point scale ranging from "never" to "always". Higher scores indicate more fatigue.

    Time frame: At Week 12

  12. Induction Study 2: Number of Participants with Clinical Remission at Week 4

    Clinical remission is defined as CDAI score\< 150.

    Time frame: At Week 4

  13. Induction Study 2: Number of Participants Reporting Both Histologic Remission and Endoscopic Remission at Week 12

    Histologic remission is defined as a Robarts Histopathology Index score \<=3, where each of the items of lamina propria neutrophils, neutrophils in epithelium, and erosions or ulcerations must be equal to 0. Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component. This is a composite endpoint defined as achieving both histologic remission and endoscopic remission at the participant level.

    Time frame: At Week 12

  14. Induction Study 2: Number of Participants with AEs and SAEs

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.

    Time frame: Up to 4 weeks after last dose of study drug (i.e., up to Week 16)

  15. Maintenance Study: Number of Participants with PRO-2 remission at Week 40

    PRO-2 remission is defined as an abdominal pain (AP) mean daily score \<= 1 and stool frequency (SF) mean daily score \<= 2.8, and no worsening of AP or SF from baseline.

    Time frame: At Week 40

  16. Maintenance Study: Number of Participants with Endoscopic Remission at Week 40

    Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component.

    Time frame: At Week 40

  17. Maintenance Study: Number of Participants with 90-Day Corticosteroid-Free Clinical Remission at Week 40

    90-day corticosteroid-free clinical remission is defined as the clinical remission at the visit and not receiving corticosteroids for at least 90 days prior to the visit. Clinical remission is defined as CDAI score \< 150.

    Time frame: At Week 40

  18. Maintenance Study: Number of Participants with Maintenance of Clinical Remission at Week 40

    Participants with clinical remission at Week 40 among those with clinical remission at Week 0 of the maintenance study will be analyzed. Clinical remission is defined as CDAI score \< 150.

    Time frame: At Week 40

  19. Maintenance Study: Number of Participants Reporting Both Clinical Remission and Endoscopic Response at Week 40

    Clinical remission is defined as CDAI score \< 150. Endoscopic response is defined as \> 50% improvement from baseline in SES-CD score or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. This is a composite endpoint defined to measure achievement of both clinical remission and endoscopic response at the participant level.

    Time frame: At Week 40

  20. Maintenance Study: Number of Participants with Deep Remission at Week 40

    Deep remission is a composite endpoint defined as achieving both clinical remission and endoscopic remission at the participant level. Clinical remission is defined as CDAI score \< 150. Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component.

    Time frame: At Week 40

  21. Maintenance Study: Number of Participants Reporting Both Histologic Remission and Endoscopic Remission at Week 40

    Histologic remission is defined as a Robarts Histopathology Index score \<=3, where each of the items of lamina propria neutrophils, neutrophils in epithelium, and erosions or ulcerations must be equal to 0. Endoscopic remission is defined as SES-CD \<= 4 with at least a 2-point reduction from baseline and no sub score \>1 in any individual component. This is a composite endpoint defined as achieving both histologic remission and endoscopic remission at the participant level.

    Time frame: At Week 40

  22. Maintenance Study: Number of Participants with IBDQ Remission at Week 40

    IBDQ remission is defined as IBDQ score \>= 170. IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate the disease-specific HRQoL across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.

    Time frame: At Week 40

  23. Maintenance Study: Number of Participants with Fatigue Response at Week 40

    Fatigue response is defined as a \>= 7 point reduction in the PROMIS-Fatigue Short Form 7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise). Item responses are rated on a five-point scale ranging from "never" to "always". Higher scores indicate more fatigue.

    Time frame: At Week 40

  24. Maintenance Study : Number of Participants with AEs and SAEs

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important.

    Time frame: Up to 4 weeks after last dose of study drug (i.e., up to Week 44)

Who is running it

Lead sponsor
Janssen Research & Development, LLC
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Janssen Research & Development, LLC
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
77242113CRD3001
Other IDs
2025-521382-27-00, 2025
  • Janssen Research & Development, LLC Clinical Trial

    Study director

    Janssen Research & Development, LLC

Study sites(395)

  • Mazumdar Shaw Medical Centre - Narayana Hrudayalaya Limited

    Bangalore, India

    Recruiting

  • Aster CMI Hospital

    Bengaluru, India

    Recruiting

  • SUM Ultimate Medicare

    Bhubaneswar, India

    Recruiting

  • Fortis Memorial Research Institute

    Gurugram, India

    Recruiting

  • Asian Institute Of Gastroenterology

    Hyderabad, India

    Recruiting

  • Yashoda Super Speciality Hospitals

    Hyderabad, India

    Recruiting

  • S. R. Kalla Memorial General Hospital

    Jaipur, India

    Recruiting

  • Lisie Hospital

    Kochi, India

    Recruiting

  • Dayanand Medical College & Hospital, Tagore Nagar, Civil Lines

    Ludhiana, India

    Recruiting

  • Fortis Hospital

    Ludhiana, India

    Recruiting

  • P D Hinduja National Hospital and Medical Research Center

    Mumbai, India

    Recruiting

  • GB Pant Institute of Post Graduate Medical Education & Research

    New Delhi, India

    Recruiting

  • All India Institute of Medical Sciences

    New Delhi, India

    Recruiting

  • Sir Ganga Ram Hospital

    New Delhi, India

    Recruiting

  • Indraprastha Apollo Hospital

    New Delhi, India

    Recruiting

  • All India Institute of Medical Sciences

    Patna, India

    Recruiting

  • Yashoda Super Speciality Hospitals 1

    Secunderabad, India

    Recruiting

  • SIDS (Surat Institute of Digestive Sciences) Hospital and Research Centre

    Surat, India

    Recruiting

  • Gujarat Gastro and Vascular Hospital

    Surat, India

    Recruiting

  • AZ Gastro Care

    Chandler, Arizona, United States

    Recruiting

  • Research Solutions of Arizona

    Litchfield Park, Arizona, United States

    Recruiting

  • Mayo Clinic

    Scottsdale, Arizona, United States

    Recruiting

  • Clinnova Research

    Anaheim, California, United States

    Recruiting

  • Southern California Research Center

    Coronado, California, United States

    Recruiting

  • Om Research, LLC 1

    Lancaster, California, United States

    Recruiting

  • TLC Clinical Research Inc

    Los Angeles, California, United States

    Recruiting

  • GastroIntestinal Bioscience

    Los Angeles, California, United States

    Recruiting

  • Hoag Memorial Hospital

    Newport Beach, California, United States

    Recruiting

  • Om Research, LLC 2

    Oxnard, California, United States

    Recruiting

  • Medical Associates Research Group, Inc.

    San Diego, California, United States

    Recruiting

  • University of California San Francisco

    San Francisco, California, United States

    Recruiting

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado, United States

    Recruiting

  • American Institute of Research

    Cutler Bay, Florida, United States

    Recruiting

  • Nature Coast Clinical Research

    Inverness, Florida, United States

    Recruiting

  • Florida Research Center Inc.

    Lakewood Rch, Florida, United States

    Recruiting

  • Sanchez Clinical Research, Inc

    Miami, Florida, United States

    Recruiting

  • GCP Clinical Research

    Tampa, Florida, United States

    Recruiting

  • Emory University

    Atlanta, Georgia, United States

    Recruiting

  • Atlanta Gastroenterology Associates

    Atlanta, Georgia, United States

    Recruiting

  • Children's Center for Digestive Health Care

    Atlanta, Georgia, United States

    Recruiting

Showing 40 of 395 sites. 382 recruiting, 13 not recruiting and 0 cancelled; 19 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes

The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Source: ClinicalTrials.gov record NCT07196722, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.